Role of interleukin-6 (IL-6) in predicting gestational diabetes mellitus

Amirian, Azam; Mahani, Mahin Balouchi; Abdi, Fatemeh

doi:10.5468/ogs.20020

Cited by 26 publications

(27 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were observed in the report of the study. PRISMA contains 27 items related to the content of a systematic and meta-analysis, and includes abstracts, methods, results, discussions, and financial resources [ 13 , 14 , 15 ]. This study was approved by ethnical code IR.ABZUMS.REC.1399.140.…”

Section: Methodsmentioning

confidence: 99%

Effect of gestational diabetes mellitus on lipid profile: A systematic review and meta-analysis

et al. 2021

Self Cite

View full text Add to dashboard Cite

Gestational diabetes mellitus (GDM) can have adverse effects on pregnancy. GDM is associated with changes in the lipid profile of pregnant women. Finding out the early ways to diagnose GDM can prevent the adverse outcomes. This meta-analysis study aimed to determine the effect of GDM on lipid profile. PubMed, ProQuest, Web of Science, Scopus, Science Direct, Google Scholar, and ClinicalTrial were systematically searched for published articles relating to GDM until 2021 according to PRISMA guidelines. Newcastle Ottawa scale was used to assess the quality of the studies. Thirty-three studies with a sample size of 23,792 met the criteria for entering the meta-analysis. Pooled standardized mean difference (SMD) for total cholesterol (TC) and triglyceride (TG) was 0.23 mg/dL (95% CI: 0.11–0.34) and 1.14 mg/dL (95% CI: 0.91–1.38), respectively. The mean of TC and TG in people with GDM was higher than that in normal pregnant women. A similar pattern was observed for the very low-density lipoprotein (VLDL) and TG/high-density lipoprotein (HDL) ratio, with pooled SMD of 0.99 mg (95% CI: 0.71–1.27) and 0.65 mg (95% CI: 0.36–0.94), respectively. Pooled SMD for HDL was −0.35 mg/dL (95% CI: −0.54 to −0.16), women with GDM had a mean HDL lower than normal pregnant women. Although pooled SMD was higher for low-density lipoprotein (LDL) in the GDM group, this difference was not significant (0.14 [95% CI: −0.04 to 0.32]). Of all the lipid profiles, the largest difference between the GDM and control groups was observed in TG (SMD: 1.14). Elevated serum TG had the strongest effect on GDM. Higher levels of TC, LDL, VLDL, and TG/HDL ratio, and lower level of HDL were exhibited in GDM group. So, these markers can be considered as a reliable marker in the diagnosis of GDM.

show abstract

Section: Methodsmentioning

confidence: 99%

Effect of gestational diabetes mellitus on lipid profile: A systematic review and meta-analysis

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Driven by the discordance in results, a recent systematic review by Amirian et al [ 155 ] has explored the relationship between Il-6 and GDM in studies published between 2009 and 2020 and included 24 articles. The study highlighted the diversity of ethnicities involved, the different measurement methods, but also the numerous criteria used to diagnose GDM (14 different diagnostic criteria) in the studies selected, making significant research synthesis difficult.…”

Section: Cytokinesmentioning

confidence: 99%

Emerging Protein Biomarkers for the Diagnosis or Prediction of Gestational Diabetes—A Scoping Review

Bogdanet

Reddin

Murphy

et al. 2021

JCM

View full text Add to dashboard Cite

Introduction: Gestational diabetes (GDM), defined as hyperglycemia with onset or initial recognition during pregnancy, has a rising prevalence paralleling the rise in type 2 diabetes (T2DM) and obesity. GDM is associated with short-term and long-term consequences for both mother and child. Therefore, it is crucial we efficiently identify all cases and initiate early treatment, reducing fetal exposure to hyperglycemia and reducing GDM-related adverse pregnancy outcomes. For this reason, GDM screening is recommended as part of routine pregnancy care. The current screening method, the oral glucose tolerance test (OGTT), is a lengthy, cumbersome and inconvenient test with poor reproducibility. Newer biomarkers that do not necessitate a fasting sample are needed for the prompt diagnosis of GDM. The aim of this scoping review is to highlight and describe emerging protein biomarkers that fulfill these requirements for the diagnosis of GDM. Materials and Methods: This scoping review was conducted according to preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines for scoping reviews using Cochrane Central Register of Controlled Trials (CENTRAL), the Cumulative Index to Nursing & Allied Health Literature (CINAHL), PubMed, Embase and Web of Science with a double screening and extraction process. The search included all articles published in the literature to July 2020. Results: Of the 3519 original database citations identified, 385 were eligible for full-text review. Of these, 332 (86.2%) were included in the scoping review providing a total of 589 biomarkers studied in relation to GDM diagnosis. Given the high number of biomarkers identified, three post hoc criteria were introduced to reduce the items set for discussion: we chose only protein biomarkers with at least five citations in the articles identified by our search and published in the years 2017–2020. When applied, these criteria identified a total of 15 biomarkers, which went forward for review and discussion. Conclusions: This review details protein biomarkers that have been studied to find a suitable test for GDM diagnosis with the potential to replace the OGTT used in current GDM screening protocols. Ongoing research efforts will continue to identify more accurate and practical biomarkers to take GDM screening and diagnosis into the 21st century.

show abstract

“…Placenta-derived inflammatory cytokines can stimulate immune cells and aggravate the immune/inflammatory response, thereby exacerbating chronic inflammation, increasing maternal IR, and inducing β cell failure during pregnancy. [42][43][44][45][46][47][48][49][50] Moreover, the immune cells and inflammatory cytokines are important parts of the placental microenvironment, which is essential for normal pregnancy. [51][52][53] The imbalanced immune infiltration in the placenta participates in the pathogenesis and development of pregnancy-specific diseases, including GDM, and may affect GDM-related adverse pregnancy outcomes and clinical prognosis.…”

Section: Inflammatory Responsementioning

confidence: 99%

Aberrantly Expressed Non-Coding RNAs in the Placenta and Their Role in the Pathophysiology of Gestational Diabetes Mellitus

Du¹,

Wu²,

L³

2021

DMSO

View full text Add to dashboard Cite

Role of interleukin-6 (IL-6) in predicting gestational diabetes mellitus

Cited by 26 publications

References 40 publications

Effect of gestational diabetes mellitus on lipid profile: A systematic review and meta-analysis

Effect of gestational diabetes mellitus on lipid profile: A systematic review and meta-analysis

Emerging Protein Biomarkers for the Diagnosis or Prediction of Gestational Diabetes—A Scoping Review

Aberrantly Expressed Non-Coding RNAs in the Placenta and Their Role in the Pathophysiology of Gestational Diabetes Mellitus

Contact Info

Product

Resources

About